Volume 10, Issue 2 (Vol.10 No.2 Jul 2021)                   rbmb.net 2021, 10(2): 302-306 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Goudhaman L, Jagadeesan A R, Sundaramoorthi S, Thotla S, Mohan S K. Association of Serum Asymmetric Dimethylarginine with the Severity of Coronary Artery Disease: A Pilot Study. rbmb.net. 2021; 10 (2) :302-306
URL: http://rbmb.net/article-1-654-en.html
Department of Biochemistry, Panimalar Medical College Hospital & Research Institute, Poonamallee, Chennai-600123, India.
Abstract:   (1369 Views)
Background: Asymmetric dimethylarginine (ADMA), an inhibitor of nitric oxide synthase (NOS), has been implicated in endothelial dysfunction and atherogenesis. Though there is much evidence linking ADMA with atherosclerosis and adverse cardiovascular events, only a few studies have established the independent relationship between elevated ADMA and the angiographic extent of coronary artery disease (CAD). The aim of the study was to analyze serum ADMA levels in patients with varied extent and severity of coronary atherosclerosis and to see whether the levels of ADMA in male and female participants vary significantly.

Methods: We analyzed 40 individuals with obstructive CAD, including men and women, between the ages of 30 and 60. According to their coronary angiographic reports, the participants were divided into four groups: minor CAD, single vessel disease (SVD), double vessel disease (DVD) group and triple vessel disease (TVD). Then, serum ADMA levels was measured and compared among these groups.

Results: ADMA level was significantly higher in patients with TVD (167.74±16.69) than those in the DVD (159.46±10.40), SVD (149.54±16.39) and minor CAD (144.5± 24.16) group (p-value= 0.0001). There was no significant difference in ADMA levels between male and female participants (p= 0.534).

Conclusions: ADMA concentration in the serum may be useful in identifying whether CAD correlates significantly to the extent and severity of coronary atherosclerosis.
Full-Text [PDF 226 kb]   (611 Downloads)    
Type of Article: Original Article | Subject: Biochemistry
Received: 2021/02/8 | Accepted: 2021/04/3 | Published: 2021/08/26

1. Mehta PK, Wei J, Wenger NK. Ischemic heart disease in women: A focus on risk factors. Trends Cardiovasc Med. 2015;25(2):140-151. [DOI:10.1016/j.tcm.2014.10.005] [PMID] [PMCID]
2. Elizabeth GN, Eugene B. A tale of coronary artery disease and myocardial infarction. N Engl J Med. 2012;366(1):54-63. [DOI:10.1056/NEJMra1112570] [PMID]
3. Sriharibabu M. Changing trends in the prevalence of coronary heart disease. Indian Heart J. 2016;68(4):445-446. [DOI:10.1016/j.ihj.2016.04.008] [PMID] [PMCID]
4. Mostafa C, Hassan A, Ali M, Esmaeel B, Salman S, Fatemeh H. Oxidative stress status and liver markers in coronary heart disease. Rep Biochem Mol Biol. 2019;8(1):49-55.
5. Abhinav Goyal, Salim Yusuf. The burden of cardiovascular disease in the Indian subcontinent. Indian J Med Res. 2006;124(3):235-44.
6. Nathan D Wong. Epidemiological studies of CHD and the evolution of preventive cardiology. Nat Rev Cardiol. 2014;11(5):276-89. [DOI:10.1038/nrcardio.2014.26] [PMID]
7. Ghaffar A, Reddy KS. Burden of non-communicable disease in South Asia. BMJ. 2004;328(7443):807-810. [DOI:10.1136/bmj.328.7443.807] [PMID] [PMCID]
8. Karsen S, Boger RH. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocystinaemia: effects of L-arginine and B vitamins. Cardiovascular Research. 2012;96(2):167-171. [DOI:10.1093/cvr/cvs205]
9. Boger RH, Stefanie MB, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, et al. Asymmetric dimethylarginine (ADMA): A novel risk factor for endothelial dysfunction. Its role in hypercholesterolemia. Circulation. 1998;98(18):1842-47. [DOI:10.1161/01.CIR.98.18.1842] [PMID]
10. Magnus P, Beaglehole R. The real contribution of the major risk factors to the coronary epidemics: time to end the "only- 50%" myth. Arch Intern Med. 2001;161(22):2657-60. [DOI:10.1001/archinte.161.22.2657] [PMID]
11. Ezzati M, Vander HS, Rodgers A, Lopez AD, Mathers CD, Murrary CJL. Estimates of global and regional health gains from reducing multiple major risk factors. Lancet. 2003;362(9380):271-80. [DOI:10.1016/S0140-6736(03)13968-2]
12. Ali A, Mohammad S, Farnaz ZA, Hossein T, Saaeedh MM, Daryoush HA, Bahare F. The status of nitric oxide and its backup, Heme oxygenase 1, in Thromboangitis obliterans. Rep Biochem Mol Biol. 2018;6(2):197-202.
13. Schulze F, Lenzen H, Hanefeld C, Bartling A, Osterziel KJ, Goudeva L, et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J. 2006;152(3):493.e1-8. [DOI:10.1016/j.ahj.2006.06.005] [PMID]
14. Miyazaki H, Matsuoka H, Cooke JP, Usui M, and Ueda S, Okuda S, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation. 1999;99(9):1141-1146. [DOI:10.1161/01.CIR.99.9.1141] [PMID]
15. Zoccali C, Bode-Boger S, Mallamaci F, Benedetto F, Tripepi G, Malatino L, et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with endstage renal disease: a prospective study. Lancet. 2001;358(9299):2113-2117. [DOI:10.1016/S0140-6736(01)07217-8]
16. Lu TM, Ding YA, Charng MJ, Lin SJ. Asymmetrical Dimethylarginine: A Novel Risk Factor for Coronary Artery Disease. Clin. Cardiol. 2003;26(10):458-64. [DOI:10.1002/clc.4960261006] [PMID] [PMCID]
17. Lu TM, Chung MY, Lin MW, Hsu CP, Lin SJ. Plasma asymmetric dimethylarginine predicts death and major adverse cardiovascular events in individuals referred for coronary angiography. Int J Cardiol. 2011;153(2):135-40. [DOI:10.1016/j.ijcard.2011.06.120] [PMID]
18. Boger RH. Asymmetric dimethylarginine (ADMA) and cardiovascular disease: insights from prospective clinical trials. Vasc Med. 2005;10 Suppl 1:S19-25. [DOI:10.1177/1358836X0501000104] [PMID]
19. Mirjana D, Sunica KD, Cabarkapa V, Eremic N. Biochemical markers of atherosclerosis. JMB. 2008;27(1):148-153. [DOI:10.2478/v10011-008-0008-1]
20. Tse-Min L, Yu-An D, Shing-Jong L, Wen-Shin L, Ho-Chang T. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J. 2003;24(21):1912-1919. [DOI:10.1016/j.ehj.2003.08.013] [PMID]
21. Cooke JP. Does ADMA cause endothelial dysfunction. Arterioscler Thromb Vasc Biol. 2000;20(9):2032-7. [DOI:10.1161/01.ATV.20.9.2032] [PMID]
22. Vinod A, Michael B, Mohammed M, Guy W, James L, Raymond MA, et al. Asymmetric Dimethylarginine Causes Hypertension and Cardiac Dysfunction in Humans and Is Actively Metabolized by Dimethylarginine Dimethylaminohydrolase. Arterioscler Thromb Vasc Biol. 2003;23(8):1455-1459. [DOI:10.1161/01.ATV.0000081742.92006.59] [PMID]
23. Olga K, Andrzej S, Alain G. Differential associations of angiographic extent and severity of coronary artery disease with asymmetric dimethylarginine but not insulin resistance in non-diabetic men with stable angina: a cross-sectional study. Cardiovasc Diabetol. 2013;12:145. [DOI:10.1186/1475-2840-12-145] [PMID] [PMCID]
24. Deneva K, Lyudmila D, Evgenia A, Todorka ZT. Plasma ADMA level in healthy people. Folia Med (Plovdiv). 2011;53(1):28-33.

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2015 All Rights Reserved | Reports of Biochemistry and Molecular Biology

Designed & Developed by : Yektaweb